Literature DB >> 21834873

Correlates of PDE5i use among subjects with erectile dysfunction in two population-based surveys.

Thomas G Travison1, Susan A Hall, William A Fisher, Andre B Araujo, Raymond C Rosen, John B McKinlay, Michael S Sand.   

Abstract

INTRODUCTION: Erectile dysfunction (ED) is thought to affect some 150 million men worldwide, but many men with ED symptoms do not seek treatment. Existing surveys suggest that men with severe ED and who report support from their partners are more likely to receive treatment than were others. Less is known, however, concerning the influence of sociomedical factors such as income and body composition on receipt of treatment. AIM: The aim of this study was to determine the importance of socioeconomic status, comorbidities, and body composition on receipt of treatment for ED symptoms.
METHODS: We used data on 638 men enrolled in the Boston Area Community Health (BACH) survey reporting ED symptoms and/or treatment for ED as evidenced by phosphodiesterase type 5 inhibitor (PDE5i) use. Logistic regression was employed to assess the relative strength of association between receipt of treatment and socioeconomic factors, body mass index, and medical factors. A replication of these results was then provided via a parallel model using the 2004 follow-up of the Men's Attitudes to Life Events and Sexuality (MALES). MAIN OUTCOME MEASURE: In BACH, ED was deemed present if a subject scored 16 points or fewer on the five-item International Index of Erectile Function or reported PDE5i use. In MALES, presence of ED was indicated by use of a validated single question querying ED severity.
RESULTS: Controlling for age, body composition and other factors, increased household income, availability of a sexual partner, and provider diagnosis of high blood pressure were positively associated with treatment seeking via the use of PDE5i therapy in BACH. Results on data available in MALES produced similar results for household income and partner availability.
CONCLUSION: These data provide evidence that financial disadvantage may present a barrier to treatment of ED, an increasingly important sentinel marker of the cardiovascular and overall health among aging men.
© 2011 International Society for Sexual Medicine.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21834873      PMCID: PMC3548233          DOI: 10.1111/j.1743-6109.2011.02423.x

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  32 in total

1.  Measuring our nation's diversity: developing a common language for data on race/ethnicity.

Authors:  K K Wallman; S Evinger; S Schechter
Journal:  Am J Public Health       Date:  2000-11       Impact factor: 9.308

Review 2.  Prevalence of erectile dysfunction: a systematic review of population-based studies.

Authors:  J Prins; M H Blanker; A M Bohnen; S Thomas; J L H R Bosch
Journal:  Int J Impot Res       Date:  2002-12       Impact factor: 2.896

Review 3.  Multiple imputation in health-care databases: an overview and some applications.

Authors:  D B Rubin; N Schenker
Journal:  Stat Med       Date:  1991-04       Impact factor: 2.373

4.  A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity.

Authors:  J Ware; M Kosinski; S D Keller
Journal:  Med Care       Date:  1996-03       Impact factor: 2.983

5.  Spontaneous remission in erectile dysfunction: a partial replication.

Authors:  R T Segraves; P Camic; J Ivanoff
Journal:  Behav Res Ther       Date:  1985

6.  Spontaneous remission in erectile impotence.

Authors:  R T Segraves; J Knopf; P Camic
Journal:  Behav Res Ther       Date:  1982

7.  Manual for scoring socioeconomic status for research on health behavior.

Authors:  L W Green
Journal:  Public Health Rep       Date:  1970-09       Impact factor: 2.792

8.  Socioeconomic factors and incidence of erectile dysfunction: findings of the longitudinal Massachussetts Male Aging Study.

Authors:  I A Aytaç; A B Araujo; C B Johannes; K P Kleinman; J B McKinlay
Journal:  Soc Sci Med       Date:  2000-09       Impact factor: 4.634

Review 9.  Endothelial dysfunction links erectile dysfunction to heart disease.

Authors:  M Kirby; G Jackson; U Simonsen
Journal:  Int J Clin Pract       Date:  2005-02       Impact factor: 2.503

10.  Drivers and barriers to seeking treatment for erectile dysfunction: a comparison of six countries.

Authors:  Ridwan Shabsigh; Michael A Perelman; Edward O Laumann; Daniel C Lockhart
Journal:  BJU Int       Date:  2004-11       Impact factor: 5.588

View more
  3 in total

1.  Predicting erectile dysfunction in sexually active patients seeking prostate health screening: proposal for a multivariable risk stratification.

Authors:  V Favilla; G I Russo; G Reale; S Leone; T Castelli; S La Vignera; R A Condorelli; A E Calogero; S Cimino; G Morgia
Journal:  Int J Impot Res       Date:  2015-07-30       Impact factor: 2.896

Review 2.  The dangers of sexual enhancement supplements and counterfeit drugs to "treat" erectile dysfunction.

Authors:  Jason Chiang; Faysal A Yafi; Philip J Dorsey; Wayne J G Hellstrom
Journal:  Transl Androl Urol       Date:  2017-02

3.  Sociodemographic patterns in pharmacy dispensing of medications for erectile dysfunction in Sweden.

Authors:  Pernilla J Bjerkeli; Shai Mulinari; Sofia Zettermark; Juan Merlo
Journal:  Eur J Clin Pharmacol       Date:  2017-11-03       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.